MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Relay Therapeutics Inc. (NASDAQ: RLAY)*
Organization & Developments: Relay Therapeutics
Parents
Relay Therapeutics Inc. (NASDAQ: RLAY)*
Children
2021: Relay Therapeutics: A Long-Term Position In Data-Driven Drug Developer Looks Attractive
2022: Relay Therapeutics (RLAY) Investor Presentation - Slideshow_seekingalpha.com
2022: Relay Therapeutics: Best-In-Class Potential PIKCA Mutation Inhibitor_ seekingalpha.com
2022: Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform_seekingalpha.com
2023: Relay Therapeutics: Market Is Underestimating Lirafugratinib's Potential (Rating Upgrade)
2024: Relay Therapeutics Has Interesting Science That Needs To Be Proven In Trials_seekingalpha.com
2024: Relay Therapeutics to Lay Off 10% of Workforce
2024: Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion
2024: Relay Therapeutics: Platform More Important Than Programs
2024: Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag
2024: Relay Therapeutics' combo therapy cuts breast cancer progression in early study
2024: Relay Therapeutics' SWOT analysis: oncology pioneer's stock faces pivotal phase
2025: Relay Therapeutics: A Precision Oncology Play Worth The Risk
2026: Relay Therapeutics: Revitalized By Breast Cancer Program, But Competition Is Intense
Jumps
*Key People: Relay Therapeutics
Finance & Acquisition: Relay Therapeutics